Form 4: Macrogenics Executive Jeffrey Peters Reports Stock Option Exercise and RSU Vesting

Jeffrey Peters, Senior VP and General Counsel of Macrogenics, reports exercising stock options and vesting of restricted stock units, resulting in changes to his beneficial ownership of company stock.

Summary

• On February 8, 2025, Jeffrey Peters, Senior VP and General Counsel of Macrogenics, exercised stock options to acquire 9,001 shares of common stock.
• He also had 9,001 restricted stock units (RSUs) vest on the same date.
• Additionally, 3,475 shares were disposed of to cover tax obligations related to the vesting of the RSUs.
• Peters was granted 105,000 employee stock options on February 7, 2025, with vesting starting six months after the grant date.
• He was also granted 18,000 restricted stock units (RSUs) on February 7, 2025, vesting annually over three years.
• Following these transactions, Peters directly owns 5,526 shares of Macrogenics common stock and 17,999 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard compensation practices and insider transactions. There are no indications of significant positive or negative developments.

Positives

• The vesting of RSUs and exercising of stock options indicates confidence in the company's future performance from a key executive.

Negatives

• The disposal of 3,475 shares to cover tax obligations could be perceived negatively, although it's a common practice.

Risks

• There are no specific risks mentioned in this document.
• However, insider transactions are always subject to scrutiny and potential legal challenges if not properly executed and disclosed.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs and stock options suggests a continued alignment of the executive's interests with the company's long-term performance.

Industry Context

Insider transactions are a common occurrence in publicly traded companies. They are closely monitored by regulators and investors to ensure compliance with securities laws and to gain insights into management's perspective on the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotechnology industry, used to incentivize and retain key executives.
• Vesting schedules, such as the one described in the document (33% annually), are typical for RSU grants.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they involve the issuance of new shares upon option exercise and the vesting of previously granted RSUs.
• Employees may view the executive's stock ownership as a positive sign of confidence in the company.

Key Dates

Keywords

Macrogenics, insider trading, Form 4, Jeffrey Peters, stock options, restricted stock units, RSU, vesting, MGNX